What do systematic reviews say?

Beta‐blockers vs placebo or no treatment

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 245 participants
  Very low

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 74 participants
  Very low

Angiotensin receptor blockers (ARBs) vs placebo or no treatment

Angiotensin receptor blockers (ARBs) leads to higher hyperkalaemia compared with placebo or no treatment (high certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 1.88 [1.07, 3.33]
  2 studies · 7148 participants
  High

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

Mineralocorticoid receptor antagonists (MRAs) leads to higher hyperkalaemia compared with placebo or no treatment (high certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 2.11 [1.77, 2.52]
  6 studies · 4291 participants
  High

Angiotensin receptor neprilysin inhibitors (ARNIs) vs usual care

Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in hyperkalaemia Range of compared with usual care (moderate certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 0.88 [0.77, 1.01]
  2 studies · 5054 participants
  Moderate